Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology,Immunology,Immunology and Allergy
Reference26 articles.
1. Compston ACC, Lassmann H, McDonald I, Miller D, Noseworthy J, Smith K, Wekerle H, editors. McAlpine’s Multiple Sclerosis. 4th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2004.
2. Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Evidence report: the efficacy and safety of mitoxantrone (novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010;74:1463–70.
3. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet. 1990;18:365–80.
4. Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;31(5):CD002127.
5. Hartung HP, Gonsette R, Ko¨nig N, et al. A placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet. 2002;360:2018–25.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献